重组干扰素α-2b治疗小儿疱疹性咽峡炎疗效及安全性的网状Meta分析  

Efficacy and safety of recombinant interferon α-2b in the treatment of herpangina in infants:a network Meta-analysis

作　　者：刘诗琪 陈黎 姚俊丽 苟小军[1,2] LIU Shiqi;CHEN Li;YAO Junli;GOU Xiaojun(Department of Paediatrics,Baoshan District Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 20199,China;不详)

机构地区：[1]上海中医药大学附属宝山医院儿科,上海201999 [2]上海市宝山区中西医结合医院中心实验室,上海201999

出　　处：《山东医药》2025年第3期96-101,共6页Shandong Medical Journal

基　　金：上海市科技计划项目(22Y11923300);上海市宝山区名中医传承工作室项目(BSMZYGZS-2024-10)。

摘　　要：目的基于网状Meta分析系统评价重组干扰素α-2b治疗小儿疱疹性咽峡炎的疗效及安全性。方法计算机检索中国生物医学文献(CBM)、中国知网、万方、维普、读秀、Ovid、Cochrane Library、Embase、PubMed、Web of Science等数据库,纳入重组干扰素α-2b治疗疱疹性咽峡炎患儿(年龄≤7岁)的随机对照试验,检索时限为建库至2024年2月27日。2名独立的研究者遵循纳入与排除标准,采用改良后的Jadad量表和Cochrane偏倚风险评估工具,对文献进行筛选、资料提取和质量评价。提取临床总有效率、退热时间、疱疹消失时间、恢复进食时间、住院时间及不良反应发生率等结局指标,通过Stata16.0软件对筛选出的文献进行Meta网状分析。结果最终纳入24篇文献,共计3078例疱疹性咽峡炎患儿,对照组干预措施包括利巴韦林、常规治疗、喜炎平、开喉剑及热毒宁等。网状Meta分析结果显示,与对照组不同干预措施相比,试验组采用重组干扰素α-2b可提高临床总有效率,缩短退热时间、疱疹消失时间、恢复进食时间、住院时间(P均<0.05),且不会增加不良反应发生率。结论对比其他治疗方案,使用重组干扰素α-2b治疗小儿疱疹性咽峡炎疗效显著,安全性较高。Objective To evaluate the efficacy and safety of recombinant interferon α-2b in the treatment of childhood herpangina through a network meta-analysis system.Methods Computerized literature searches were conducted in CBM,CNKI,Wanfang,VIP,Duxiu,Ovid,Cochrane Library,Embase,PubMed,and Web of Science databases.Included studies were randomized controlled trials of recombinant interferon α-2b for treating herpangina in children(≤7 years old),with a retrieval period from database construction to February 27,2024.Two independent researchers adhered to inclusion and exclusion criteria,and we employed an improved Jadad scoring tool and the Cochrane bias risk assessment tool to screen and extract literature,as well as to evaluate study quality.Outcome indicators included clinical total efficacy rates,time to reduce fever,time for vesicle disappearance,time to resume feeding,hospitalization time,and incidence of adverse reactions.The Stata16.0 software was utilized to conduct network Meta-analysis on the screened studies.Results Twenty-four studies involving 3,078 cases of herpangina in children were ultimately included.The intervention measures in the control group included ribavirin,conventional therapy,xiyanping,kaihoujian,and reduning.Network Meta-analysis revealed that compared with different intervention measures in the control group,recombinant interferon α-2b in the experimental group could improve clinical total efficacy rates,shorten fever time,vesicle disappearance time,time to resume feeding,and hospitalization time,without increasing the incidence of adverse reactions.Conclusion Compared with the other treatment schemes,the use of recombinant interferon α-2b for the treatment of childhood herpangina demonstrated significant efficacy and higher safety.

关 键 词：重组干扰素Α-2B 疱疹性咽峡炎 网状Meta分析 

分 类 号：R725.6[医药卫生—儿科]